JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

This study is testing a new treatment called JK-1201I combined with the standard chemotherapy drug temozolomide in patients with newly diagnosed glioblastoma (an aggressive brain cancer) after they complete standard chemoradiation. **You may be eligible if...** - You are between 18 and 75 years old - You have been newly diagnosed with glioblastoma (confirmed by imaging or pathology) - At least 80% of your tumor was removed during surgery - You have completed concurrent chemoradiation therapy between 4 and 6 weeks ago - Your steroid dose has been stable or decreasing for at least 2 weeks - Your general health and organ function are adequate (Karnofsky score 70 or above) - For one part of the study: your tumor must have MGMT unmethylation (a specific tumor characteristic) **You may NOT be eligible if...** - You received any other anti-cancer therapy besides chemoradiation - Your tumor is in the brain stem or spinal cord - You are allergic to JK-1201I ingredients - You have serious uncontrolled heart problems - You have uncontrolled seizures Talk to your doctor to see if this trial is right for you.